| Business Summary | | Protein
Design
Labs,
Inc
is
engaged
in
the
development
of
humanized
monoclonal
antibodies
for
the
prevention
and
treatment
of
disease.
The
Company
has
licensed
certain
rights
to
its
first
humanized
antibody
product,
Zenapax,
to
Hoffmann-La
Roche
Inc.
and
its
affiliates
(Roche),
which
markets
Zenapax
for
the
prevention
of
kidney
transplant
rejection.
The
Company
is
also
testing
Zenapax
for
the
treatment
of
autoimmune
disease.
In
addition,
the
Company
has
several
other
humanized
antibodies
in
clinical
development
for
autoimmune
and
inflammatory
conditions,
asthma
and
cancer.
The
Company
has
fundamental
patents
in
the
United
States,
Europe
and
Japan,
that
cover
many
humanized
antibodies.
Eleven
companies
have
licenses
under
these
patents
for
humanized
antibodies
that
they
have
developed.
The
Company
receives
royalties
on
sales
of
the
three
humanized
antibodies
developed
by
other
companies
that
are
currently
being
marketed. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | PDLI
develops
human
and
humanized
antibodies
and
other
potential
drugs
to
prevent
or
treat
certain
disease
conditions,
including
viral
infections,
autoimmune
diseases
and
certain
cancers.
For
the
six
months
ended
6/30/01,
revenues
increased
33%
to
$47.8
million.
Net
income
increased
69%
to
$9.8
million.
Revenues
reflect
increased
interest
income.
Earnings
also
reflect
decreased
research
and
development
expenses
as
a
percentage
of
revenues. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Laurence Korn, Ph.D., 51 CEO
and Chairman | $446K | $19.9M | Cary Queen, Ph.D., 50 Sr.
VP, VP, Research | 316K | 11.7M | Douglas Ebersole, 54 Sr.
VP, Licensing and Corp. Services, Sec. | 366K | 5.2M | Daniel Levitt, M.D., Ph.D., 54 Sr.
VP of Clinical and Regulatory Affairs | 389K | 6.9M | Sergio Garcia-Rodriguez VP,
Legal, Gen. Counsel and Assistant Sec. | -- | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|